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Enteric absorption of ciprofloxacin during tube feeding in the
critically ill

Section of Trauma/Surgical Critical Care, Department of Surgery, Yale School of
Medicine, 333 Cedar Street, New Haven, CT 06520, USA

To determine the pharmacokinetic properties of ciprofloxacin in the critically ill, we
studied seven mechanically ventilated patients with pneumonia during entcral
feedings. Subjects received ciprofloxacin 750 mg every 12 h via nasogastric tube and
serial serum drug concentrations were measured after the first and fourth dose. After
the initial dose, the maximum serum concentration ranged from 1.24-3.06 mg/L, and
the area under the time curve from 0-12 h ranged from 3.2-19.65 mg.h/L. Similar
levels were noted after dose four. Gastrointestinal absorption of ciprofloxacin in tube
fed critically ill patients was decreased, but well above MIC values for many
pathogenic bacteria.

Introduction

Ciprofloxacin has been demonstrated to have broad antimicrobial activity, excellent
tissue penetration, long duration of action and good bioavailability (Bergan, 1988).
These factors increase the likelihood of therapeutic efficacy and make oral ciprofloxacin
a potential alternative to parenteral antibiotics in patients with functioning
gastrointestinal tracts. Ciprofloxacin may be particularly useful in treatment of
nosocomial respiratory tract infections because most respiratory tract pathogens are
susceptible. A large multicentre trial showed parenteral ciprofloxacin to be as efficacious
(69% clinical response rate) as imipenem-cilastatin (59%) in the treatment of
severe nosocomial pneumonia (Fink et al., 1994). Studies have also shown the oral
form of ciprofloxacin to have comparable cure rates to parenteral antibiotics in the
sequential treatment (parenteral followed by oral form) of serious bacterial respiratory
tract infections, limiting the need for parenteral antibiotics and leading to substantial
cost savings (Khan & Basir, 1989; Paladino et al., 1991).
Previously, we demonstrated that gastrointestinal absorption of ciprofloxacin is
unpredictable in critically ill patients immediately after major abdominal procedures,
when gut function is diminished (Cohn et al., 1995). We felt that critically ill patients
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with functioning gastrointestinal tracts, as demonstrated by tolerance of tube feedings,
would be likely to absorb oral drugs. Therefore, we hypothesized that ciprofloxacin
administered via nasogastric tube would be sufficiently absorbed to achieve therapeutic
serum concentrations in this intensive care unit population.

Materials and methods
Antibacterial agent
Ciprofloxacin (Bayer Corp., Pharmaceutical Division, West Haven, CT, USA) was
administered in 750 mg doses via nasogastric tube every 12 h for 48 h (total of four
doses). The tablets were pulverized and added to 50 mL of sterile water before
administration. The nasogastric tube was flushed with 30 mL of sterile water to ensure
that the entire dose was delivered into the stomach. After introduction of the drug into
the stomach, the nasogastric tube was reattached to the feeding pump and Pulmocare
enteral feedings were resumed. No other oral medications (e.g., carafate or antacids)
were given during this study. The patients received stress ulcer prophylaxis in the form
of H2 receptor antagonists, intravenously.

Subjects
Seven subjects (two female, five male) with a mean age of 52 years (range 34-71)
consented to participate in this investigation. Subjects were included in the study if they
were at least eighteen years of age, required mechanical ventilation, were receiving
parenteral antibiotics for treatment of a documented pneumonia (fever, leukocytosis,
positive sputum, and new infiltrate on chest x-ray), and had tolerated tube feeding for
at least forty-eight hours. Subjects received Pulmocare as their enteral feeding mixture
(calcium = 1.04 mg/mL; magnesium = 0.62 mg/mL; iron = 0.02 mg/mL). Subjects
were excluded from the study for any of the following reasons: (1) history of
hypersensitivity to quinolones; (2) pregnant or lactating women; (3) receipt of
ciprofloxacin within one week of this study; (4) receipt of another investigational drug
within 4 weeks prior to drug administration; (5) renal impairment indicated by
creatinine greater than 3.0 mg/dL or creatinine clearance less than 40 mL/min.; (6)
significant liver dysfunction defined as total bilrubin greater than 3 mg%; (7)
granulocytopenia with granulocytes less than 1 x 106/L; (8) chronic inflammatory bowel
disease; (9) history of pseudomembranous colitis; (10) concomitant administration of
probenecid during the study. Prior approval for this protocol was obtained from the
Human Investigation Committee, and written informed consent was obtained. Data
regarding the subjects' age, weight, pre-existing medical conditions, and APACHE II
score were tabulated (see Table I).

Sampling
Blood samples were collected for drug assay from existing arterial or central venous
catheters before administration of the drug and at 0.25, 0.5, 0.75, 1.0, 1.25, 2.0, 4.0,
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Table I. Demographics
Vent days
12.7
37.3
11.0
15.9
12.7
16.0
12.1
16.8
11 to 37.3

WBC

S/P fall
motor vehicle crash
respiratory failure
motor vehicle crash
pedestrian injury
motor vehicle crash
stabbed to left flank

Diagnosis

E-Lap, Exploratory laparotomy; ORIF, open reduction and internal fixation of fraction, N/A, not applicable.

Age

Patient

N/A
tracheostomy
N/A
E-Lap
N/A
ORIF, E-Lap
E-Lap

Surgical procedure

3
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Table II. Pharmacokinetics
Patient
1
2
3
4
5
6
7

Mean
S.E.M.

Range

r
2.89
1.73
3.06
1.24
2.40
2.46
2.26
2.29
0.24
1.24 to 3.06

Dose 1

AUCo_l2

0.50
0.50
1.0
2.0
2.0
0.75
0.25
1.0
0.27
0.25 to 2.0

13.69
3.20
10.44
7.48
19.65
8.64
6.16
9.90
2.05
3.20 to 19.65

Dose 4
3.43
2.50
1.49
1.20
3.76
1.22
2.04
2.23
0.39
1.20 to 3.76

AUCo.l2

0.50
16.81
0.50
4.32
1.25
11.68
2.0
7.04
1.0
19.26
1.5
6.21
0.50
9.12
1.04
10.63
2.11
0.22
0.50 to 2.0 4.32 to 19.26

Cm«, Maximum serum concentration (mg/L); 7"™,, time to reach maximum concentration (h);
AUCo-12, area under the serum concentration time curve from time 0 to time 12 h (mg.h/L).

12.0 h after doses one and four. Within 2 h of phlebotomy, samples were centifuged
(20 min at 3200 rpm at 4°C), and the supernatant stored in glass vials at — 70°C.
Samples were shipped on dry ice to Bayer Corporation for drug assay.
Assay
Ciprofloxacin assay was performed by Bayer Corporation, Pharmaceutical Division,
Clinical Pharmacology Laboratory. Serum concentrations were determined by
high-performance liquid chromatography (Krol, Noe, & Beermann, 1986). The limit
of sensitivity of this assay was 0.05 mg/L. The assay was linear over the range of
0.05-7.5 mg/L. The coefficient of variation associated with the intra-day precision and
accuracy was less than 10% at all concentrations examined.
Statistical and pharmacokinetic analysis
Pharmacokinetic variables were determined using noncompartmental models.
Maximum serum concentrations and time to maximum serum concentration were
determined directly from the serum concentration time curve derived from the
observed data following the first and last dose (steady state). The area under the
curve values for each dose interval were determined by the log-linear trapezoidal
method.
Results
The seven subjects had a mean APACHE II score of 9.3 (range 5-17) (see Table I). The
maximum serum concentration (CM,), time to reach C™, (T^), and the area under the
curve for serum concentration versus time from r = 0 - 1 2 h (AUCo-12) are listed in
Table II for each subject. Values are means ± S.E.M.
When comparing mean data for all patients, pharmacokinetics for the first and
fourth dose were similar (dose 1: C ^ = 2.29 ± 0.24 mg/L, T^ = 1.0 ± 0.27 h,
AUCo-12 = 9.90 ± 2.05 mg.h/L; dose 4: C ^ = 2.23 ± 0.39 mg/L, Tmtx=\.04±
0.22 h,
AUCo-12 = 10.63 ± 2.11 mg.h/L). However, examination of the individual dose-response curves shows a moderate degree of variability.
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Discussion
The principle finding of this study was that oral absorption of the 750 mg ciprofloxacin
dose in critically ill patients was moderate, but variable. We chose to study enteric
absorption of ciprofloxacin in mechanically ventilated patients with pneumonia because
these individuals frequently have functioning gastrointestinal tracts and require
antibiotic therapy. Pharmacokinetic analysis was performed on a heterogeneous group
(in terms of patient age, type and severity of medical illnesses) which reflects the typical
intensive care unit population.
Ciprofloxacin is well absorbed during enteral feeding in normal volunteers with a C^,
of 2.92 ± 0.32 mg/L, and AUCV12 = 15.02 ± 1.55 mg.h/L which were similar to the
findings noted in our critically ill population (Yuk et al., 1989). Reduced gastrointestinal
absorption of the drug with enteral feedings has been related to chelation by divalent
cations (Mueller et al., 1994). Ciprofloxacin absorption is diminished when patients are
given Pulmocare when compared to Ensure or Osmolite, probably reflecting the fact
that Pulmocare has twice the concentration of calcium and magnesium (Mueller et al.,
1994). In our study, serum ciprofloxacin concentrations after the initial study dose
(C,™ = 2.29 ± 0.24 mg/L and AUC0-12 = 9.9 ± 2.05 mg.h/L) were similar to those seen
in normal volunteers after receiving a 500 mg oral dose (C^, = 2.7 + 0.2 mg/L and
AUC0-12 = 10.7 ± 0.8 mg.h/L) (Lettieri et al., 1992). These serum levels were well above
MICs for many important pathogenic bacteria. Chelation by divalent cations in the tube
feeding solution probably contributed to the variability and reduction in drug
absorption seen in our subjects. Use of alternative enteral feeding mixtures with lower
concentrations of divalent cations or stopping tube feedings for a short period of time
may result in improved drug absorption.
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